Therapeutic Asset Ratings

374 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Orca-T Acute Myeloid Leukemia	Orca Biosystems, Inc.	P3	B (58)
PEGASPARGASE Acute Myeloid Leukemia	Janssen Research & Development, LLC	P3	B (58)
Pembrolizumab Acute Myeloid Leukemia	Joanna Yi	P3	B (58)
Sargramostim Acute Myeloid Leukemia	Sellas Life Sciences Group	P3	B (58)
Selinexor Acute Myeloid Leukemia	Donghua Zhang	P3	B (58)
Solu-Cortef Acute Myeloid Leukemia	Children's Oncology Group	P3	B (58)
Bendamustine Acute Myeloid Leukemia	St. Petersburg State Pavlov Medical University	P2	B (58)
DARATUMUMAB Acute Myeloid Leukemia	City of Hope Medical Center	P2	B (58)
Mesna Acute Myeloid Leukemia	Center for International Blood and Marrow Transplant Research	P2	B (58)
Ponatinib Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P2	B (58)
Arsenic Trioxide Acute Myeloid Leukemia	The University of Hong Kong	P3	B (57)
Fluconazole Acute Myeloid Leukemia	Bochud Pierre-Yves	P3	B (57)
Lipitor Acute Myeloid Leukemia	Loyola University	P3	B (57)
Uproleselan Acute Myeloid Leukemia	National Cancer Institute (NCI)	P3	B (57)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Myeloid Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2	B (57)
Itraconazole Acute Myeloid Leukemia	Mansoura University	P2	B (57)
Alpha-Interferon Acute Myeloid Leukemia	Peking University People's Hospital	P4	B (56)
L-Ofloxacin Acute Myeloid Leukemia	University of Manitoba	P3	B (56)
PENTOSTATIN Acute Myeloid Leukemia	OHSU Knight Cancer Institute	P3	B (56)
Vorinostat Acute Myeloid Leukemia	Medical College of Wisconsin	P3	B (56)
Carboplatin Acute Myeloid Leukemia	Joanna Yi	P2	B (56)
Ciml-Nk Cells Acute Myeloid Leukemia	Children's Hospital Medical Center, Cincinnati	P2	B (56)
Hydroxyurea Acute Myeloid Leukemia	Uma Borate	P2	B (56)
Ruxolitinib Phosphate Acute Myeloid Leukemia	City of Hope Medical Center	P2	B (56)
Sitagliptin Acute Myeloid Leukemia	Indiana University	P2	B (56)

Showing 76 to 100 of 374 assets

PreviousPage 4 of 15Next